NOVEL DOSAGE FORM OF PALIPERIDONE AND PROCESS FOR PREPARING THE SAME

• US 20110177137A1
• Filed: 09/14/2009
• Published: 07/21/2011
• Est. Priority Date: 09/15/2008
• Status: Abandoned Application

• Current Assignee: Intas Pharmaceuticals Limited
• Original Assignee: Intas Pharmaceuticals Limited
• Inventors: Patel, Sanjay Maganbhai, Maheshwari, Kirti Bansidhar, Mandal, Jayanta Kumar, Dhavale, Satyavan Shivajirao, Chauhan, Vijaysinh Vanvirsinh
• Application Number:
  US13/063,836
• Publication Number:
  US 20110177137A1
• Time in Patent Office: Days
• US Class Current: 424/400
• CPC Class Codes: A61K 9/2846 Poly(meth)acrylates
• CPC Class Codes: A61K 9/2853 obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
• CPC Class Codes: A61K 9/2866 Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
• CPC Class Codes: A61K 9/2886 having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer of the type active core-drug layer-inactive layer A61K9/209
• CPC Class Codes: A61P 25/18 Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Abstract

The present invention relates to an extended release composition of paliperidone for oral administration comprising paliperidone and at least one matrixing agent. The said extended release composition maintains desired therapeutic drug effect over a prolonged period of time and thereby reduces the side effects resulting due to excess drug blood plasma concentration. Further, the invention also relates to process for the preparation of an extended release oral composition of paliperidone.

Claims

1. ) An extended release composition of paliperidone for oral administration comprising an active ingredient and at least one matrixing agent in a ratio of 1:

1 to 1;

20 respectively.

2. ) The composition as claimed in claim 1, wherein the in-vitro release of the active ingredient is at least 50% within 12 hours.

3. ) The composition as claimed in claim 1, further comprises of at least one of the pharmaceutically acceptable ingredients selected from diluent 5-95%, binder 1-25%, antioxidant 0.05-2% or lubricant 0.5-10%.

4. ) The composition as claimed in claim 1, wherein the said matrixing agent comprises of natural or synthetic agents selected from the group comprising polysaccharides such as xanthan, pullulan, chitosan and the like;

gums like guar gum, gum arabic, gum karaya, and the like;

cellulose ethers, such as hydroxymethylcellulose (HMC), hydroxyethylcellulose (HEC), hydroxypropylcellulose (HPC), methylcellulose (MC), ethylcellulose (EC), carboxyethylcellulose (CEC), ethylhydroxyethylcellulose (EHEC), carboxymethylhydroxyethylcellulose (CMHEC), hydroxypropylethylcellulose (HPEC), hydroxypropylmethylcellulose (HPMC) and sodium carboxymethylcellulose (Na CMC);

polymeric methacrylates;

carbomers as well as copolymers and/or mixtures thereof of the above agents.

5. ) The composition as claimed in claim 1, wherein at least one matrixing agent is intra-granular and/or extra-granular;

wherein the intra-granular or extra-granular agents are same or different.

6. ) The composition as claimed in claim 1, additionally comprises of a pH independent polymer coating.

7. ) The polymer coating as claimed in claim 6, wherein the said pH independent polymer coating composition comprises of low water permeable polymer, plasticizer, opacifiers and colorants.

8. ) A process for the preparation of an extended release composition of paliperidone for oral administration which comprises of an active ingredient and at least one matrixing agent;

wherein the process comprises of the following steps;

a) Blending paliperidone and at least one intra-granular matrixing agent to form a first blend,

b) Granulating the first blend using a binding solution to form granulates,

c) Blending the granulates obtained in step b) with at least one extra-granular matrixing agent, and

d) Compressing the second blend obtained in step c) into tablet.

9. ) The process as claimed in claim 8, additionally comprising a pH independent polymer coating.

10. ) The process as claimed in claim 8, wherein at least one intra-granular matrixing agent and atleast one extra-granular matrixing agent are the same or different.